📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. (2020)

First Author: Phillips RO

Attributed to: R Phillips, KNUST Ghana. Pathogenesis and management of M. ulcerans disease, Buruli ulcer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(20)30047-7

PubMed Identifier: 32171422

Publication URI: http://europepmc.org/abstract/MED/32171422

Type: Journal Article/Review

Volume: 395

Parent Publication: Lancet (London, England)

Issue: 10232

ISSN: 0140-6736